Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from GT Biopharma ( (GTBP) ) is now available.
On August 26, 2025, GT Biopharma, Inc. announced an amendment to the employment agreement with Michael Breen, renewing his position as CEO for two years effective April 29, 2025. This renewal signifies the company’s commitment to stable leadership, potentially impacting its strategic direction and stakeholder confidence positively.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
GT Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative immuno-oncology products.
Average Trading Volume: 97,567
Technical Sentiment Signal: Sell
Current Market Cap: $3.44M
For detailed information about GTBP stock, go to TipRanks’ Stock Analysis page.